Neo-B

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neo-B

Property Description
Active ingredients Bacitracin, Neomycin
Form Ointment, Sterile Powder
Pharmacological class Combination Antibiotic, Topical Antimicrobial Agent
Common use Anti-infective action against superficial bacteria
Origin Synthetic/Semi-synthetic

What Type of Medicine is Neo-B?

Neo-B is a recognized brand of a fixed-dose combination antibiotic and topical antimicrobial agent, specifically designed for application on the skin. It utilizes two distinct, powerful active ingredients, Bacitracin (a polypeptide antibiotic) and Neomycin (an aminoglycoside antibiotic), to achieve its anti-infective purpose. The formulation is designed to provide broad anti-infective coverage against common superficial pathogens. The active components themselves are generally considered of synthetic or semi-synthetic origin, derived through microbiological or chemical modification processes.


Neo-B Composition and Form

The core composition of Neo-B involves the active substances Bacitracin and Neomycin, typically available as a smooth ointment or a sterile powder. The ointment form utilizes an inert hydrocarbon base, such as petrolatum, which helps to deliver the active ingredients and keep them localized at the application site. As a dermatological preparation, the medication is intended solely for topical administration, primarily targeting minor wounds and scrapes in a general patient group, distinguishing its use from internal or prescription-only treatments. These components utilize two distinct mechanisms of action—one disrupting the bacterial cell wall and the other protein synthesis—as integral to the product’s function.


General Purpose and Action of Neo-B

The general purpose of Neo-B is to stop the proliferation of susceptible bacteria on the skin through its potent, dual-action bactericidal effect. The combination provides a synergistic effect, allowing the preparation to effectively limit bacterial growth across a wide variety of common surface organisms. This capability is utilized in scenarios such as applying the ointment to minor cuts and abrasions to prevent subsequent bacterial colonization. This broad-spectrum action is the primary benefit, facilitating the definitive clearance of organisms and serving as a comprehensive anti-infective measure for superficial skin injuries.

What side effects are possible with Neo-B?

Possible Side Effects and Safety Information

Neo-B (hydroxocobalamin) has an established safety profile with documented adverse reactions classified by system-organ class. The most common adverse reactions reported involve the Gastrointestinal (e.g., nausea, vomiting, diarrhoea) and Nervous Systems (e.g., headache, dizziness), as well as Skin and Subcutaneous Tissue (e.g., acne, skin rash, pruritus). Injection-site pain and redness are also commonly reported effects.

Clinically Significant and Serious Reactions

Serious adverse reactions are considered rare but include anaphylaxis and other severe hypersensitivity reactions. The drug is contraindicated in patients with a known hypersensitivity to the drug substance, any excipients, or cobalt. Cardiovascular events, such as cardiac arrest and pulmonary oedema or congestive heart failure, have been reported, particularly during the initial intensive phase of treating megaloblastic anaemia; close monitoring of serum potassium is required in this context. Peripheral vascular thrombosis has also been documented.

Safety Restrictions and Monitoring

Neo-B must NOT be used intravenously. Long-term parenteral administration carries a risk of aluminium toxicity in patients with renal impairment and in preterm infants. The drug administration causes chromaturia (a pink/reddish colour in urine, blood, and body fluids) and may interfere with certain laboratory tests (e.g., creatinine, bilirubin, total proteins, glucose) due to its light-absorbing properties. Caution is advised when administering to patients with known cobalt allergy, and a sensitivity test dose may be recommended.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Neo-B overdose is primarily concerned with the consequences of systemic absorption of the active ingredients, Neomycin and Bacitracin, which may occur following excessive topical use or application to large areas of broken skin.

Documented Overdose Manifestations and Risks

Suspected systemic overdose is associated with the potential for nephrotoxicity (kidney damage) and ototoxicity (damage to the ear, affecting hearing and balance). Severe or life-threatening outcomes documented in regulatory labeling include acute renal failure and respiratory paralysis resulting from neuromuscular blockade.

Required Emergency Actions

Regulators explicitly mandate that individuals seek immediate medical attention for any known or suspected overdose or for the manifestation of systemic toxicity signs. Urgent medical care is required if severe effects such as balance issues, acute hearing changes, or difficulty breathing are observed. The official regulatory advice states that symptomatic and supportive treatment is the necessary management procedure, and that no specific antidote is known for this toxicity.

Monitoring and Special Considerations

Hospital monitoring is required for suspected overdose and typically includes specific renal function monitoring and auditory function assessment. An increased risk of systemic toxicity is noted for patients with pre-existing renal impairment and in pediatric patients due to higher relative absorption risk.

Therapeutic Uses of Neo-B

Main Uses and Symptomatic Benefits

The therapeutic use of a Vitamin B-complex product containing high doses of B1, B6, and B12 serves as supportive assistance in the management of painful neurological symptoms. Neo-B is used in contexts marked by increased discomfort or tension, making it suitable for conditions involving episodic or fluctuating symptoms.

Neo-B is generally applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort and symptoms of increased neurological or muscular activity. It is commonly used for conditions characterized by periods of heightened symptoms and involving recurrent or episodic manifestations.

The medication may assist with groups of symptoms associated with conditions such as:

  • Neuritis and Polyneuritis (nerve inflammation)
  • Neuralgia (nerve pain)
  • Lumbago (lower back pain)
  • Ischialgia and Sciatica

“It provides symptomatic support that helps patients cope more steadily during difficult episodes.”

When symptoms become temporarily overwhelming and create noticeable functional strain, Neo-B may help provide supportive relief. It plays a role in managing acute symptom flare-ups, contributing to improved day-to-day comfort.


Quick Fact: Relevant for Temporary Functional Discomfort

Regulatory References

  1. FDA Philippines Product Information for Vitamin B-complex

Eligibility and Restrictions for Use

Who Can and Cannot Use Neo-B?

The official eligibility criteria for using Neo-B (Bacitracin and Neomycin topical combination) are defined by the medicine's regulatory label, focusing on absolute contraindications and restrictions based on patient population and site of application.


Contraindicated Populations

Category Non-Eligibility Statement
Allergies Contraindicated in individuals with hypersensitivity to Bacitracin, Neomycin, or related aminoglycoside antibiotics (e.g., Kanamycin, Gentamycin).
Pre-existing Conditions Contraindicated in patients with pre-existing nerve deafness where significant systemic absorption may occur.
Infection Type Contraindicated for tuberculous, fungal, or viral lesions of the skin (e.g., herpes simplex).

Restricted and Conditional Use

Population Group Regulatory Status
Infants/Children Not recommended for use in neonates and infants (under 2 years of age).
Pregnancy Not recommended for use during pregnancy due to theoretical risk of fetal harm (ototoxicity).
Lactation Caution should be exercised; it is not known if the drug is excreted in human milk.
Organ Function Caution must be exercised in cases of decreased renal function due to the risk of systemic absorption.

Site and Extent of Application

  • Must not be used in the eyes or applied over large areas of the body.
  • Application to deep or puncture wounds, animal bites, or serious burns requires medical consultation.

What should I know about interactions with other medicines?

Neo-B Interactions with other medicines and products

This section outlines the documented interaction information for Neo-B (Bacitracin and Neomycin), which primarily relates to the potential for systemic absorption of Neomycin when the product is applied to large areas, denuded skin, or serious burns.


Documented Interaction Patterns

The regulatory profile mandates caution or avoidance with several classes of medicinal products due to the risk of enhanced toxicity:

  • Additive Toxicity Risk: Concurrent or sequential use with other aminoglycosides or polypeptide antibiotics is officially noted to increase the risk of neurotoxicity and renal dysfunction through additive effects.
  • Diuretics: Co-administration with potent diuretics such as furosemide or ethacrynic acid is documented to enhance systemic toxicity by altering the concentration of the Neomycin component in tissues.
  • Neuromuscular Agents: Combining Neomycin with anesthetics or neuromuscular-blocking agents (e.g., tubocurarine) is formally described as carrying the risk of neuromuscular blockade and respiratory paralysis.

These interaction constraints are deemed most relevant in patients with preexisting renal damage, those who are dehydrated, or those of advanced age, as these conditions may increase the potential for drug accumulation and resulting systemic effects.

Mechanism of Action

Neo-B operates by engaging a dual-action bactericidal mechanism targeting two distinct, life-essential processes simultaneously.

Disruption of Bacterial Cell Wall Construction

The mechanism begins with Bacitracin, which acts as an inhibitor by binding to the essential lipid carrier, Undecaprenyl Pyrophosphate ( C55 -PP). This molecular action blocks the final transport of cell wall building blocks, causing the cell wall assembly pathway to halt. The resulting defective cell wall structure is unable to withstand normal osmotic pressure, triggering the lysis and destruction of the bacterial cell.

Inhibition of Internal Protein Synthesis

The complementary mechanism involves Neomycin, an aminoglycoside that binds specifically to the bacterial 30S ribosomal subunit. This molecular interaction disrupts the translation process, leading to the incorporation of incorrect amino acids and the synthesis of aberrant, non-functional proteins. The accumulation of these faulty proteins compromises the bacterial cell's internal metabolic function and its cell membrane integrity, resulting in a parallel bactericidal effect.

Synergistic Dual-Pathway Action

These two mechanisms are crucial because they operate on entirely different and non-cross-resistant biological targets. The synergistic effect supports broad coverage of microbial targets by assaulting both the bacteria's external structure and its internal metabolic machinery. The combination leverages non-cross-resistant targets, which is a mechanism-based strategy to overcome single-pathway failure.

Dosage and Administration Information

The administration of Neo-B is indicated for the topical route, meaning it is designed solely for application onto the surface of the skin. The product is typically presented in two standard dosage forms: a smooth ointment and a sterile powder. Application involves using a small amount to create a thin film that covers the entire affected area. This uniform application is essential for following the standard regimen.


The typical schedule for this topical antibiotic requires application one to three times daily. The procedural use begins with the requirement to clean the affected site thoroughly before application. The product is for external use only, and is not for use in areas such as the eyes or on large body surface areas. A critical procedural constraint is the treatment duration, which is to be completed within a period of no more than seven days.


Regarding specific population groups, Neo-B is intended for adults and children two years of age and older. Use in children under the age of two requires specific guidance from a healthcare provider to ensure proper application. Adherence to the scheduled frequency and the mandatory duration limit constitutes the standard protocol for using Neo-B.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical research has evaluated the drug's effect on pain and explored whether it may be associated with a change in chronic and acute pain experience. Findings from initial studies suggest that the drug may be associated with improvements in the pain experience.


Studies on Chronic Pain Management

Studies focused on chronic pain have largely explored conditions such as osteoarthritis and chronic lower back pain.

  • One large-scale study reported a reduction in pain scores for patients with long-term osteoarthritis.
  • Research investigating the use for chronic lower back pain showed mixed findings, with some trials suggesting a change in patient-reported pain intensity and others reporting minimal change compared to placebo.

The greatest change in patient-reported outcomes was observed in studies where the drug was used in conjunction with physical therapy. Research in this area has investigated whether this combined approach is associated with improved mobility.


Research on Acute Pain

Studies on acute pain have focused on postoperative pain and short-term injury-related pain.

  • A meta-analysis examined the drug’s use in the immediate postoperative period and reported on the investigated dosage for an observed change in pain intensity compared to other common post-surgical medications. It did not make a comparison to other treatments.
  • Other trials explored whether the drug is associated with a reduced reliance on rescue medication following minor injuries. The duration of this observed effect was highly variable across the studies.

Research Focus and Limited Evidence Areas

Overall, research has explored the drug's proposed action, which involves the enzyme X. The drug's primary clinical research has focused on adult populations.

  • Some preliminary research has explored whether the drug is associated with changes in the experience of migraine, but the evidence base in this area remains limited.
  • Studies are currently enrolling participants to investigate the drug in pediatric populations. No final data is available yet.

Key Studies & References

  1. ClinicalTrials.gov Registry Entry for Ongoing Pediatric Pain Management Study of Neo-B

Frequently Asked Questions (FAQ)

Common questions about Neo-B (FAQ)

Q: How long does the effect of Neo-B usually last?

Regulatory documents state that to maintain the anti-infective effect on the skin, Neo-B is intended to be applied one to three times daily. This frequency of application is consistent with the established regimen required to maintain the presence of the active ingredients at the site of application.


Q: What are the most reported side effects of Neo-B?

According to official product information, the most frequently reported adverse reaction is allergic sensitization, which might appear as a rash, itching, or swelling of the skin. More serious, but less common, effects like ototoxicity (damage to the inner ear) and nephrotoxicity (kidney damage) are reported when the Neomycin component is absorbed into the bloodstream.


Q: Can I drive or operate machinery while taking Neo-B?

The official label does not provide a specific directive regarding driving or operating machinery for topical use. However, nervous system effects, such as dizziness or numbness and tingling, have been associated with Neomycin if it is absorbed systemically. Awareness of the potential for these effects is generally advised.


Q: Is Neo-B intended for short-term or long-term use?

Neo-B is intended for short-term use. Official guidelines for self-medication state that the product should not be used for longer than one week. The recommended protocol for use, if the condition persists or worsens after this period, involves consulting a healthcare provider.


Q: Why does Neo-B have a 'Black Box Warning' (if applicable)?

The topical product itself does not typically carry this warning. However, the systemic (parenteral) form of the component Neomycin, an aminoglycoside antibiotic, carries a Boxed Warning regarding the potential for serious toxicity. This warning specifically highlights the risk of nephrotoxicity (kidney damage) and ototoxicity (ear damage).


Q: Are there any specific foods or drinks I need to avoid while taking Neo-B?

Official medical information indicates that the topical product is not generally associated with specific food or drink restrictions. Unless otherwise advised by a healthcare provider, individuals using the medication can generally continue their normal diet.


Q: Can I drink coffee while using Neo-B?

As a topical medication, official product information does not indicate any specific interactions with coffee. Unless instructed otherwise by a healthcare provider, individuals using Neo-B are generally permitted to maintain their normal consumption of drinks like coffee.


Q: What happens if I forget to take a dose of Neo-B?

Regulatory product information describes the protocol for a missed dose, which is to apply it as soon as it is remembered. However, the protocol advises skipping the missed application if it is almost time for the next scheduled application to prevent over-application.


Q: Are there long-term risks associated with using Neo-B?

Prolonged use beyond the maximum recommended one-week duration is discouraged by regulatory warnings. Regulatory warnings state that use beyond the recommended duration is associated with an increased potential for the overgrowth of non-susceptible organisms or the development of cutaneous sensitization (allergic skin reactions) related to the Neomycin component.


Q: What is the recommended approach for discontinuing Neo-B?

Treatment should not be continued for longer than one week, which serves as a natural endpoint. Official warnings describe conditions that warrant discontinuing use and consulting a healthcare provider, such as when the treated condition persists or worsens, or if symptoms of a rash or other allergic reaction develop at the application site.


Q: Why do some people stop taking Neo-B?

The official label notes that reasons for discontinuation, as described in the warnings and adverse reactions sections, include when the condition being treated persists or worsens, or when symptoms suggestive of a rash or allergic reaction develop.


Q: How long do people typically stay on Neo-B treatment?

For self-medication, official guidelines state that the product should be used for up to one week. Use longer than this mandatory period requires consulting a healthcare provider, establishing the typical duration as seven days or less.


Q: Is Neo-B available over the counter, or is it prescription-only?

The official label indicates that Neo-B is available without a prescription for self-medication for minor skin infections. This classifies it as an over-the-counter or non-prescription medicine.


Q: What should I do if I experience an unusual side effect while on Neo-B?

Official instructions describe the protocol for an unusual side effect as contacting a doctor. Regulatory guidance also provides the option for patients or doctors to report serious side effects to the FDA MedWatch Adverse Event Reporting program.

How should Neo-B be stored and disposed of?

Storage and Disposal of Neo-B

Official regulatory guidelines mandate specific conditions for storing and disposing of this topical antibiotic product to maintain its stability and ensure safety.


Storage Conditions

Neo-B must be stored at controlled room temperature (20 to 25 C) and kept away from excess heat and moisture. The product should not be frozen. It must remain in its original container and be kept tightly closed when not in use. For child safety, the medication must be stored out of sight and reach of children.


Disposal Instructions

Unused or expired Neo-B must not be flushed down the toilet or washed down the sink. The preferred disposal method is a medicine take-back program. If unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neo-B found in:

A-Z Index: